MCL Literature Feed

A case report demonstrates that MCL can relapse in rare sites like skeletal muscle after rituximab maintenance, underscoring the value of PET/CT for detecting atypical disease progression.

This review details diverse BTKi resistance mechanisms beyond BTK mutations, providing a framework for developing next-generation inhibitors and combination strategies to overcome treatment failure in MCL.

Single-cell RNA sequencing reveals pre-existing, minor therapy-resistant subclones at diagnosis, which are selected during treatment, explaining early relapse and highlighting cell-cycle dysregulation as a common resistance mechanism.

In real-world relapsed/refractory MCL, ibrutinib dose reduction to manage toxicity is common and does not compromise response rates, PFS, or OS, validating this as a practical clinical strategy.

In a large real-world analysis, R-CHOP/R-DHAP trended toward better OS in transplant-eligible patients, while rituximab maintenance, not initial chemo, drove survival in transplant-ineligible patients.

PRMT5 inhibition sensitizes MCL cells to ferroptosis by disrupting the ATF5-SLC7A11 axis, providing a rationale for combining PRMT5 inhibitors with ferroptosis inducers for relapsed/refractory disease.

Single-cell multi-omics reveals genetic and non-genetic pirtobrutinib resistance mechanisms in MCL, identifying the cohesin complex as a potential target to restore drug sensitivity.

A deep learning model fusing PET/CT and EHR data creates a new signature that better predicts survival in frontline MCL, potentially improving risk-adapted therapy selection.

Consensus guidelines recommend the BOVen triplet (zanubrutinib, obinutuzumab, venetoclax) for TP53-mutated MCL and CAR-T for BTKi-refractory disease, providing expert guidance for managing high-risk patients.

This review outlines the evolving MCL treatment paradigm, detailing the integration of BTKi, CAR-T, and bispecific antibodies in both frontline and relapsed/refractory settings to improve patient outcomes.

This case report identifies a rare, aggressive MCL variant with blastoid morphology, TdT expression, and MYC rearrangement, broadening the known clinicopathological spectrum and posing significant diagnostic challenges.

A real-world, retrospective study demonstrates that clinical next-generation sequencing panels provide significant prognostic and predictive data in mantle cell lymphoma, aiding in the optimization of patient management.

This case report describes the rare co-occurrence of MCL and a pancreatic neuroendocrine tumor, highlighting a diagnostic pitfall where lymphadenopathy can originate from either malignancy, complicating staging.

Genomic analysis reveals MCL relapse is driven by the expansion of pre-existing resistant subclones, not new mutations, highlighting the need for deep sequencing at diagnosis to prevent recurrence.

This case report details severe, reversible myocarditis from bortezomib, a rare but critical cardiotoxicity for clinicians to recognize in MCL patients receiving proteasome inhibitor-based therapy.

CT-guided anterior approach biopsy is a safe and effective minimally invasive technique for diagnosing orbital lymphoma, including mantle cell lymphoma, providing an alternative to more invasive surgical procedures.

Preclinical data suggests PRMT5 inhibition is a promising combination therapy strategy for high-risk MCL with ATM and TP53 mutations, which are known to confer therapeutic resistance.

Mitochondrial ACSS1 enables nutrient-stressed B-cell lymphomas to produce DNA/RNA building blocks via acetate metabolism, identifying ACSS1 as a novel therapeutic target to overcome metabolic adaptation.